Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 9, 2023 at 04:01 PM.
Here’s what investors need to know about the announcement.
Earnings
Halozyme Therapeutics missed estimated earnings by 2.08%, reporting an EPS of $0.47 versus an estimate of $0.48.
Revenue was up $44.86 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.01 which was followed by a 0.85% increase in the share price the next day.
Here’s a look at Halozyme Therapeutics’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | 0.47 | 0.51 | 0.50 | 0.49 |
| EPS Actual | 0.48 | 0.74 | 0.53 | 0.47 |
| Revenue Estimate | 192.05M | 191.10M | 138.78M | 128.25M |
| Revenue Actual | 181.50M | 208.98M | 152.37M | 117.28M |
To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
